$ARWR

Goldman Sachs initiated coverage on Arrowhead Pharmaceuticals (ARWR) with a Neutral rating and $74 price target, citing slight overvaluation. ARWR's Q3 2026 revenue beat estimates at $75.2M, but net loss widened. RBC and Stifel maintained positive ratings with higher targets, citing pipeline progress and clinical trial results.

Arrowhead Pharmaceuticals reported interim Phase 1/2a data for ARO-DIMER-PA, showing 72% silencing of PCSK9 and 88% of APOC3 with no serious adverse events. Analysts project $1.0B revenue and $176M earnings by 2029, with a 66% potential upside. The company plans to file for severe hypertriglyceridemia approval for REDEMPLO by year-end.

Arrowhead Pharmaceuticals (ARWR) is amending a study to add a multidose portion in mixed-hyperlipidemia patients before a Phase III study. The company reported smooth launch progress for plozasiran in familial chylomicronemia syndrome (FCS) and plans to seek approval in severe hypertriglyceridemia (SHTG). Arrowhead expects to provide further details on additional dimer candidates in 2027. The company's current net price for plozasiran is $45,000 annually. Arrowhead is also developing programs in

Arrowhead Pharmaceuticals (ARWR) plans to submit a supplemental new drug application for plozasiran in severe hypertriglyceridemia (SHTG) by year-end, with Phase 3 trials showing about an 80% reduction in triglycerides. The company acquired a priority review voucher, which could reduce review timing by four months. Arrowhead estimates plozasiran could become a $3 billion to $4 billion annual U.S. drug at peak. The company also provided updates on its zodasiran program in homozygous familial hype

Arrowhead Pharmaceuticals plans to file a supplemental application for its drug Redemplo by year-end, with CEO Chris Anzalone projecting peak U.S. sales of $3B-$4B. The company's pipeline includes zodasiran for rare high-cholesterol conditions. ARWR stock has seen a 2% year-to-date increase, with 8 analysts rating it a 'Buy'.

Arrowhead Pharmaceuticals (ARWR) reported early positive data for ARO-DIMER-PA, showing reductions in bad cholesterol and triglycerides. The company expects peak sales of $3-$4B for Redemplo and highlighted a strong pipeline. Retail traders on Stocktwits have turned 'extremely bullish' on ARWR, with some buying on recent selloffs. ARWR stock is up 2% year-to-date.

Arrowhead Pharmaceuticals (ARWR) presented at the H.C. Wainwright conference, highlighting its RNAi platform's expansion. The company launched REDEMPLO for FCS and targets a major SHTG launch by 2027. Pivotal trials showed strong efficacy and safety, with new programs in obesity, CNS, and dimer technology.

Arrowhead Pharmaceuticals reported interim Phase I/IIa trial results for ARO-DIMER-PA, showing dose-dependent reductions in PCSK9 (72%) and APOC3 (88%) in mixed hyperlipidaemia patients. The treatment also reduced LDL-C (54%), triglycerides (73%), and other lipids. No serious adverse events were reported. The trial is ongoing to assess repeat dosing. According to the company, this marks the first clinical validation of targeting two genes simultaneously with RNAi therapeutics.

Arrowhead Pharmaceuticals (ARWR) fell 8.93% to $73.47 after announcing interim Phase 1/2a trial data for ARO-DIMER-PA, an RNAi therapeutic targeting PCSK9 and APOC3 genes. The company reported robust reductions in LDL-C and other lipoproteins, validating its Targeted RNAi Molecule platform.

Arrowhead Pharmaceuticals (ARWR) reported promising Phase 1/2a trial results for ARO-DIMER-PA, showing significant reductions in key lipid markers. The company's P/S ratio is 16.9x, below its historical median but still high. GF Value™ estimates ARWR is 59.6% overvalued. Insider activity shows no buying and $36.3M in selling. ARWR has a GF Score™ of 49, reflecting mixed fundamentals.